A vaccine in a year? An insight into how the world's biggest pharma company is taking on the industry's ultimate challenge

3 November 2020

Given that the task of tackling the coronavirus pandemic is arguably the biggest – and certainly the highest profile – challenge that the pharmaceutical industry has faced this century, it is appropriate that the world’s largest pharma company is among the leaders of the race to find a vaccine.

Pfizer (NYSE: PFE) and Germany’s BioNTech (Nasdaq: BNTX) could file for US emergency use approval of their two-dose COVID-19 vaccine, known as BNT162b2, later this month.

Clinical data on BNT162b2 is currently being submitted to other regulatory agencies, including the European Medicines Agency and Health Canada, under a ‘rolling review’ procedure which is intended to speed up the process.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK